Trial reportJournal of neurosurgery2008
Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases.
Trial report in Journal of neurosurgery, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 84 citations in OpenAlex.
- Pooled it
- Trial
- A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma.Neuro-oncology · 2011Trial
- A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma.Journal of neuro-oncology · 2009Trial
- Bevacizumab Alone Versus Bevacizumab Plus Irinotecan in Patients With Recurrent Glioblastoma: A Nationwide Population-Based Study.Journal of Korean medical science · 2024Article
- Unlocking Bevacizumab's Potential: rCBVCancers · 2023Article
- Anaplerotic nutrient stress drives synergy of angiogenesis inhibitors with therapeutics targeting tumor metabolism.bioRxiv : the preprint server for biology · 2023Article
- Cancer cell heterogeneity & plasticity in glioblastoma and brain tumors.Seminars in cancer biology · 2022Review
- Natural killer cell therapy potentially enhances the antitumor effects of bevacizumab plus irinotecan in a glioblastoma mouse model.Frontiers in immunology · 2022Article
- Glioma progression is suppressed by Naringenin and APO2L combination therapy via the activation of apoptosis in vitro and in vivo.Investigational new drugs · 2020Article
- Clinical outcomes in recurrent glioblastoma with bevacizumab therapy: An analysis of the literature.Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia · 2017Review
- Optimizing bevacizumab dosing in glioblastoma: less is more.Journal of neuro-oncology · 2017Article
- New Directions in Anti-Angiogenic Therapy for Glioblastoma.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2017Review
- Bevacizumab in Recurrent Glioma: Patterns of Treatment Failure and Implications.Brain tumor research and treatment · 2017Review
- Cost-effectiveness analysis of the bevacizumab-irinotecan regimen in the treatment of primary glioblastoma multiforme recurrences.Oncology letters · 2016Article
- Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?Oncotarget · 2016Review
- Efficient Production of a Bioactive Bevacizumab Monoclonal Antibody Using the 2A Self-cleavage Peptide in Transgenic Rice Callus.Frontiers in plant science · 2016Article
- Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2015Article
- Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience.Radiology and oncology · 2015Article
- The future of high-grade glioma: Where we are and where are we going.Surgical neurology international · 2015Article
Corrections and comments
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectEndothelial proliferation has been recognized as a marker of high-grade or aggressive glioma. Bevacizumab is a humanized immunoglobulin G1 monoclonal antibody to vascular endothelial growth factor that has been shown to have activity in malignant gliomas when combined with irinotecan. The authors report on a case series of 13 patients with recurrent heavily pretreated malignant glioma that was treated with the combination of bevacizumab and irinotecan.
methodsStandard therapy with primary resection followed by adjuvant chemotherapy and radiation had failed in all patients. The median number of therapies applied, including initial surgery, was 5 (range 3-7 therapies). Nine patients were started on bevacizumab at a dose of 5 mg/m2 every 2 weeks. Four patients received bevacizumab at a dose of 10 mg/m2; irinotecan was given at a dose of 125 mg/m2 every week for 3 weeks.
resultsOf the 13 treated patients, 10 (77%) had a radiologically demonstrated partial response and 3 (23%) had stable disease. Six patients (46%) had a clinical response. The median time to disease progression while on treatment was 24 weeks. The median overall survival was 27 weeks. The disease progressed in 8 patients, despite an initial response. Five patients are still responding to therapy. Six of the 8 patients whose disease progressed have died. Bevacizumab was discontinued in 2 patients because of nonfatal intracranial bleeding.
conclusionsThe combination of bevacizumab and irinotecan is safe and has excellent activity even in this relapsed, heavily pretreated population of patients with high-grade malignant glioma, most of whom would not be candidates for clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.